{
    "clinical_study": {
        "@rank": "11762", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Beta Glucosylceramide", 
                "arm_group_type": "Active Comparator", 
                "description": "Beta Glucosylceramide"
            }
        ], 
        "brief_summary": {
            "textblock": "Oral administration of betaglucosylceramide was shown effective in reducing inflammation in\n      animal models and was found safe in humans."
        }, 
        "brief_title": "Beta Glucosylceramide for Treatment of NASH", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Compliance Behavior", 
        "detailed_description": {
            "textblock": "Patients with NASH to receive the treatment versus placebo for 40 weeks followed by  a liver\n      biopsy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy proven NASH\n\n        Exclusion Criteria:\n\n          -  Other therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126306", 
            "org_study_id": "YI1958"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "Beta Glucosylceramide"
                ], 
                "description": "Beta Glucosylceramide", 
                "intervention_name": "Beta Glucosylceramide", 
                "intervention_type": "Drug", 
                "other_name": "Beta Glucosylceramide"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Beta Glucosylceramide"
                ], 
                "description": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "number_of_arms": "2", 
        "official_title": "Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis", 
        "overall_official": {
            "affiliation": "Hadassah Medical Center", 
            "last_name": "Yaron Ilan, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Decrease of 2 points in the biopsy score", 
            "measure": "Liver biopsy score measured by points of the NAS score", 
            "safety_issue": "Yes", 
            "time_frame": "40 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hadassah Medical Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2006"
    }
}